Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Conmed (CNMD) Acquisitions (2016 - 2022)

Conmed filings provide 7 years of Acquisitions readings, the most recent being $642000.0 for Q4 2022.

On a quarterly basis, Acquisitions changed N/A to $642000.0 in Q4 2022 year-over-year; TTM through Dec 2023 was $85.2 million, a 0.0% change, with the full-year FY2022 number at $227.7 million, changed N/A from a year prior.
Acquisitions hit $642000.0 in Q4 2022 for Conmed, down from $84.5 million in the prior quarter.
In the past five years, Acquisitions ranged from a high of $364.9 million in Q1 2019 to a low of $642000.0 in Q4 2022.